Ibrahim H. Eissa

7.7k total citations · 1 hit paper
206 papers, 6.6k citations indexed

About

Ibrahim H. Eissa is a scholar working on Organic Chemistry, Molecular Biology and Toxicology. According to data from OpenAlex, Ibrahim H. Eissa has authored 206 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Organic Chemistry, 115 papers in Molecular Biology and 44 papers in Toxicology. Recurrent topics in Ibrahim H. Eissa's work include Synthesis and biological activity (89 papers), Bioactive Compounds and Antitumor Agents (43 papers) and Computational Drug Discovery Methods (40 papers). Ibrahim H. Eissa is often cited by papers focused on Synthesis and biological activity (89 papers), Bioactive Compounds and Antitumor Agents (43 papers) and Computational Drug Discovery Methods (40 papers). Ibrahim H. Eissa collaborates with scholars based in Egypt, Saudi Arabia and United States. Ibrahim H. Eissa's co-authors include Ahmed M. Metwaly, Eslam B. Elkaeed, Hazem Elkady, Khaled El‐Adl, Ahmed B. M. Mehany, Hazem A. Mahdy, Aisha A. Alsfouk, Ahmed A. Al‐Karmalawy, Mohammed S. Taghour and Helmy Sakr and has published in prestigious journals such as PLoS ONE, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Ibrahim H. Eissa

197 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular Docking and Dynamics Simulation Revealed the Potential Inhibitory Activity of ACEIs Against SARS-CoV-2 Targeting the hACE2 Receptor

2021 209 citations Mohammed A. Dahab, Ahmed M. Metwaly et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ibrahim H. Eissa Egypt	52	4.2k	3.2k	1.1k	1.0k	1.0k	206	6.6k
Wagdy M. Eldehna Egypt	53	5.0k 1.2×	3.9k 1.2×	585 0.5×	556 0.5×	902 0.9×	262	7.4k
Ahmed M. Metwaly Egypt	38	2.0k 0.5×	1.9k 0.6×	957 0.9×	575 0.6×	505 0.5×	167	4.0k
Hatem A. Abdel‐Aziz Egypt	51	5.2k 1.2×	2.8k 0.9×	358 0.3×	403 0.4×	607 0.6×	266	6.6k
Hsing‐Pang Hsieh Taiwan	44	2.1k 0.5×	2.3k 0.7×	603 0.5×	212 0.2×	832 0.8×	152	5.3k
Chunquan Sheng China	52	4.1k 1.0×	4.5k 1.4×	474 0.4×	383 0.4×	1.4k 1.4×	263	9.3k
Curtis Hose United States	22	1.6k 0.4×	2.3k 0.7×	197 0.2×	385 0.4×	1.2k 1.2×	31	4.7k
Zhi‐Shu Huang China	48	2.4k 0.6×	5.2k 1.6×	526 0.5×	341 0.3×	456 0.5×	249	8.0k
Ahmed B. M. Mehany Egypt	34	1.8k 0.4×	1.2k 0.4×	309 0.3×	357 0.3×	349 0.3×	73	2.7k
Chunlin Zhuang China	33	1.7k 0.4×	2.4k 0.7×	226 0.2×	203 0.2×	519 0.5×	159	4.7k
Om Silakari India	29	2.5k 0.6×	1.3k 0.4×	557 0.5×	163 0.2×	361 0.4×	112	4.5k

Countries citing papers authored by Ibrahim H. Eissa

Since Specialization

Citations

This map shows the geographic impact of Ibrahim H. Eissa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ibrahim H. Eissa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ibrahim H. Eissa more than expected).

Fields of papers citing papers by Ibrahim H. Eissa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ibrahim H. Eissa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ibrahim H. Eissa. The network helps show where Ibrahim H. Eissa may publish in the future.

Co-authorship network of co-authors of Ibrahim H. Eissa

This figure shows the co-authorship network connecting the top 25 collaborators of Ibrahim H. Eissa. A scholar is included among the top collaborators of Ibrahim H. Eissa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ibrahim H. Eissa. Ibrahim H. Eissa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Elgammal, Walid E., Hazem Elkady, Reda G. Yousef, et al.. (2025). New nicotinamide–thiadiazol hybrids as VEGFR-2 inhibitors for breast cancer therapy: design, synthesis and in silico and in vitro evaluation. RSC Advances. 15(18). 14477–14498. 4 indexed citations

Elkady, Hazem, Hazem A. Mahdy, Mohammed S. Taghour, et al.. (2024). New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies. Biochimica et Biophysica Acta (BBA) - General Subjects. 1868(6). 130599–130599. 13 indexed citations

Eissa, Ibrahim H., Hazem Elkady, Walid E. Elgammal, et al.. (2024). Integrated in silico and in vitro discovery of a new anticancer thiadiazole analog targeting VEGFR-2. Journal of Molecular Structure. 1312. 138641–138641. 13 indexed citations

Mahdy, Hazem A., Hazem Elkady, Walid E. Elgammal, et al.. (2024). Design, synthesis, in vitro, and in silico studies of new thiadiazol derivatives as promising VEGFR-2 inhibitors and apoptosis inducers. Journal of Molecular Structure. 1316. 139019–139019. 15 indexed citations

Eissa, Ibrahim H., Reda G. Yousef, Hazem Elkady, et al.. (2024). Design and In Silico and In Vitro Evaluations of a Novel Nicotinamide Derivative as a VEGFR-2 Inhibitor. Journal of Chemistry. 2024. 1–25. 2 indexed citations

Yousef, Reda G., Ibrahim H. Eissa, Hazem Elkady, et al.. (2024). Design and synthesis of new nicotinamides as immunomodulatory VEGFR-2 inhibitors and apoptosis inducers. Future Medicinal Chemistry. 16(24). 2583–2598. 4 indexed citations

Elkady, Hazem, Mohammed S. Taghour, Mohammed A. Dahab, et al.. (2023). New thiazolidine-2,4-diones as effective anti-proliferative and anti-VEGFR-2 agents: Design, synthesis, in vitro, docking, MD simulations, DFT, ADMET, and toxicity studies. Computational Biology and Chemistry. 107. 107958–107958. 16 indexed citations

El‐Metwally, Souad A., Hazem Elkady, Mohamed Hagras, et al.. (2023). Design, synthesis, anti-proliferative evaluation, docking, and MD simulation studies of new thieno[2,3-d]pyrimidines targeting VEGFR-2. RSC Advances. 13(33). 23365–23385. 15 indexed citations

Eissa, Ibrahim H., Reda G. Yousef, Hazem Elkady, et al.. (2023). A Theobromine Derivative with Anticancer Properties Targeting VEGFR‐2: Semisynthesis, in silico and in vitro Studies. ChemistryOpen. 12(10). e202300066–e202300066. 11 indexed citations

10.

Al-Mijalli, Samiah H., Emad M. Abdallah, Ibrahim H. Eissa, et al.. (2023). Galactoside-Based Molecule Enhanced Antimicrobial Activity through Acyl Moiety Incorporation: Synthesis and In Silico Exploration for Therapeutic Target. Pharmaceuticals. 16(7). 998–998. 5 indexed citations

11.

Metwaly, Ahmed M., et al.. (2023). Discovery of Anti‐Breast Cancer Thiophene Sulfonamide Derivatives: Design, Synthesis, Molecular Docking against EGFR, MM‐PBSA, MD Simulations, ADME/Tox, and in vitro Studies. ChemistrySelect. 8(27). 2 indexed citations

12.

Elkaeed, Eslam B., Mohammed S. Taghour, Hazem A. Mahdy, et al.. (2022). New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies. Journal of Enzyme Inhibition and Medicinal Chemistry. 37(1). 2191–2205. 58 indexed citations

13.

Elwan, Alaa, Abdallah E. Abdallah, Hazem A. Mahdy, et al.. (2022). Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation. Molecules. 27(15). 5047–5047. 51 indexed citations

14.

Фазылов, С. Д., et al.. (2022). Combined Computational and Experimental Studies of Anabasine Encapsulation by Beta-Cyclodextrin. Plants. 11(17). 2283–2283. 9 indexed citations

15.

Alesawy, Mohamed S., Abdallah E. Abdallah, Mohammed S. Taghour, et al.. (2021). In Silico Studies of Some Isoflavonoids as Potential Candidates against COVID-19 Targeting Human ACE2 (hACE2) and Viral Main Protease (Mpro). Molecules. 26(9). 2806–2806. 53 indexed citations

16.

Hagras, Mohamed, Marwa A. Saleh, Emad Gamil Khidr, et al.. (2021). 1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and in silico studies. Journal of Enzyme Inhibition and Medicinal Chemistry. 37(1). 386–402. 38 indexed citations

17.

Metwaly, Ahmed M., Mohammed M. Ghoneim, Ibrahim H. Eissa, et al.. (2021). Traditional ancient Egyptian medicine: A review. Saudi Journal of Biological Sciences. 28(10). 5823–5832. 105 indexed citations

18.

Suleimen, E. M., Masayoshi Oyama, Eslam B. Elkaeed, et al.. (2021). Isolation and In Silico Anti-COVID-19 Main Protease (Mpro) Activities of Flavonoids and a Sesquiterpene Lactone from Artemisia sublessingiana. Journal of Chemistry. 2021. 1–8. 26 indexed citations

19.

Suleimen, E. M., et al.. (2020). Isolation and biological evaluation of roseofungin and its cyclodextrin inclusion complexes. 100(4). 35–44. 3 indexed citations

20.

Eissa, Ibrahim H., Abeer M. El‐Naggar, Nour E. A. Abd El‐Sattar, & Ahmed S. A. Youssef. (2018). Design and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors. Anti-Cancer Agents in Medicinal Chemistry. 18(2). 195–209. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact